351 related articles for article (PubMed ID: 29361094)
21. Infliximab in young paediatric IBD patients: it is all about the dosing.
Jongsma MME; Winter DA; Huynh HQ; Norsa L; Hussey S; Kolho KL; Bronsky J; Assa A; Cohen S; Lev-Tzion R; Van Biervliet S; Rizopoulos D; de Meij TGJ; Shouval DS; Wine E; Wolters VM; Martinez-Vinson C; de Ridder L;
Eur J Pediatr; 2020 Dec; 179(12):1935-1944. PubMed ID: 32813123
[TBL] [Abstract][Full Text] [Related]
22. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
23. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
Merras-Salmio L; Kolho KL
J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
[TBL] [Abstract][Full Text] [Related]
26. Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease.
van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
J Pediatr Gastroenterol Nutr; 2019 Jun; 68(6):847-853. PubMed ID: 30633108
[TBL] [Abstract][Full Text] [Related]
27. Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment.
Rolandsdotter H; Marits P; Sundin U; Wikström AC; Fagerberg UL; Finkel Y; Eberhardson M
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272355
[TBL] [Abstract][Full Text] [Related]
28. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.
Dreesen E; Van Stappen T; Ballet V; Peeters M; Compernolle G; Tops S; Van Steen K; Van Assche G; Ferrante M; Vermeire S; Gils A
Aliment Pharmacol Ther; 2018 Feb; 47(3):346-355. PubMed ID: 29226370
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
30. Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity.
Dubinsky MC; Mendiolaza ML; Phan BL; Moran HR; Tse SS; Mould DR
Inflamm Bowel Dis; 2022 Sep; 28(9):1375-1385. PubMed ID: 34978325
[TBL] [Abstract][Full Text] [Related]
31. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
Roblin X; Duru G; Williet N; Del Tedesco E; Cuilleron M; Jarlot C; Phelip JM; Boschetti G; Flourié B; Nancey S; Peyrin-Biroulet L; Paul S
Inflamm Bowel Dis; 2017 Jan; 23(1):126-132. PubMed ID: 28002129
[TBL] [Abstract][Full Text] [Related]
32. Infliximab desensitization in patients with inflammatory bowel diseases: a safe therapeutic alternative.
Hammoudi N; Hassid D; Bonnet J; Tran Minh ML; Baudry C; Vauthier A; Chedouba L; Houzé P; Lourenco N; Aparicio T; Gornet JM; Allez M
Scand J Gastroenterol; 2024 May; 59(5):553-560. PubMed ID: 38353236
[TBL] [Abstract][Full Text] [Related]
33. Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease.
Minar P; Saeed SA; Afreen M; Kim MO; Denson LA
J Pediatr Gastroenterol Nutr; 2016 May; 62(5):715-22. PubMed ID: 26551317
[TBL] [Abstract][Full Text] [Related]
34. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.
Selinger CP; Lenti MV; Clark T; Rafferty H; Gracie D; Ford AC; OʼConnor A; Ahmad T; Hamlin PJ
Inflamm Bowel Dis; 2017 Dec; 23(12):2083-2088. PubMed ID: 29140939
[TBL] [Abstract][Full Text] [Related]
35. One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study.
Hong SN; Hye Song J; Jin Kim S; Ha Park Y; Wan Choi C; Eun Kim J; Ran Kim E; Kyung Chang D; Kim YH
Inflamm Bowel Dis; 2024 Apr; 30(4):517-528. PubMed ID: 37260346
[TBL] [Abstract][Full Text] [Related]
36. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
[TBL] [Abstract][Full Text] [Related]
37. Individualized Infliximab Treatment Guided by Patient-managed eHealth in Children and Adolescents with Inflammatory Bowel Disease.
Carlsen K; Houen G; Jakobsen C; Kallemose T; Paerregaard A; Riis LB; Munkholm P; Wewer V
Inflamm Bowel Dis; 2017 Sep; 23(9):1473-1482. PubMed ID: 28617758
[TBL] [Abstract][Full Text] [Related]
38. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis.
Moore H; Dolce P; Devas N; Baldassano R; Martinelli M
United European Gastroenterol J; 2020 May; 8(4):425-435. PubMed ID: 32213038
[TBL] [Abstract][Full Text] [Related]
39. Success and safety of high infliximab trough levels in inflammatory bowel disease.
Drobne D; Kurent T; Golob S; Svegl P; Rajar P; Terzic S; Kozelj M; Novak G; Smrekar N; Plut S; Sever N; Strnisa L; Hanzel J; Brecelj J; Urlep D; Osredkar J; Homan M; Orel R; Stabuc B; Ferkolj I; Smid A
Scand J Gastroenterol; 2018 Aug; 53(8):940-946. PubMed ID: 29987967
[TBL] [Abstract][Full Text] [Related]
40. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study.
Tran-Minh ML; Gornet JM; Maillet M; Houze P; Simon M; McLellan P; Hassid D; Vivier-Chicoteau J; Baudry C; Hammoudi N; Allez M
J Crohns Colitis; 2021 May; 15(5):742-748. PubMed ID: 33205193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
